Novo mesto, 05 July (STA) - The shareholders of drug maker Krka earmarked on Thursday more than EUR 50m from a total of over EUR 172.7m in distributable profit for dividends at EUR 1.50 gross apiece. In the first half of the year, the firm's revenues reached EUR 565m, up 7% over first six months of last year.
Krka CEO Jože Colarič told the press after the meeting that EUR 61.3m would go for provisions, while an equal amount would be carried over as distributable profit for next year.
The company's sales on the domestic market have however dropped slightly, he noted. Lower sales were recorded also in central Europe.
The sales figures were significantly up only in the countries of eastern Europe - Russia, Ukraine, Uzbekistan and Kazakhstan - and few countries of western Europe, the CEO said.
Colarič expects sales in central Europe to return to levels from previous years by the end of 2012, but does not believe this will be the case in Slovenia.
The shareholders meeting also gave its approval to the management's work in last year and appointed Ljubljana-based subsidiary of Ernst & Young auditor for 2012.